Mindbio Therapeutics begins trading on OTCQB

Executive Summary

• Mindbio Therapeutics Corp. has listed its common shares for trading on the OTCQB market, expanding its investor base to include U.S. investors.
• The listing coincides with the launch of an extended roadshow for its voice and AI-powered drug and alcohol intoxication technology in the United States.
• The company is developing an enterprise version of its technology and a new platform for health prediction using human voice analytics, with plans to announce progress on new products and commercial applications shortly.

Key Details

• Listing Venue: OTCQB Market.
• Technology: AI model using over 50 million data points to predict alcohol intoxication via human voice; estimates actual blood alcohol concentration levels.
• Product Launch: Successful 2025 launch of the "Booze AI app."
• Target Markets: Workplace environments, call centres, mental health, and law enforcement.
• Strategic Focus: Development of an enterprise version and new platform-level technology for health prediction using the human voice.
• CEO Commentary: Justin Hanka stated the listing allows the company to reach U.S. investors interested in AI and predictive health technologies.

Notable Quotes

• "We are pleased to now reach U.S. investors and a much larger investor audience, particularly those U.S. investors interested in AI and predictive health technologies, via our OTCQB listing." — Justin Hanka, Chief Executive Officer